Eli Lilly Debt to Equity Ratio 2006-2018 | LLY

Current and historical debt to equity ratio values for Eli Lilly (LLY) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Eli Lilly debt/equity for the three months ending September 30, 2018 was 0.83.
Eli Lilly Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2018-09-30 $11.68B $14.15B 0.83
2018-06-30 $9.17B $11.62B 0.79
2018-03-31 $9.39B $14.59B 0.64
2017-12-31 $9.94B $11.67B 0.85
2017-09-30 $9.93B $14.96B 0.66
2017-06-30 $9.87B $14.17B 0.70
2017-03-31 $7.64B $14.10B 0.54
2016-12-31 $8.37B $14.08B 0.59
2016-09-30 $8.71B $15.62B 0.56
2016-06-30 $8.69B $14.66B 0.59
2016-03-31 $7.48B $15.03B 0.50
2015-12-31 $7.97B $14.59B 0.55
2015-09-30 $8.07B $15.24B 0.53
2015-06-30 $7.99B $14.71B 0.54
2015-03-31 $7.42B $14.95B 0.50
2014-12-31 $5.33B $15.39B 0.35
2014-09-30 $5.29B $17.68B 0.30
2014-06-30 $5.30B $18.00B 0.30
2014-03-31 $5.26B $18.35B 0.29
2013-12-31 $4.20B $17.64B 0.24
2013-09-30 $4.26B $16.90B 0.25
2013-06-30 $4.29B $15.24B 0.28
2013-03-31 $4.43B $14.96B 0.30
2012-12-31 $5.52B $14.77B 0.37
2012-09-30 $5.51B $16.06B 0.34
2012-06-30 $5.50B $14.31B 0.38
2012-03-31 $5.40B $14.82B 0.37
2011-12-31 $5.47B $13.54B 0.40
2011-09-30 $5.45B $15.06B 0.36
2011-06-30 $5.20B $14.28B 0.36
2011-03-31 $5.13B $13.93B 0.37
2010-12-31 $6.77B $12.41B 0.55
2010-09-30 $6.98B $12.41B 0.56
2010-06-30 $6.86B $10.24B 0.67
2010-03-31 $6.66B $10.46B 0.64
2009-12-31 $6.64B $9.53B 0.70
2009-09-30 $6.77B $9.91B 0.68
2009-06-30 $6.69B $8.56B 0.78
2009-03-31 $6.87B $7.73B 0.89
2008-12-31 $4.62B $6.74B 0.69
2008-09-30 $4.19B $13.74B 0.31
2008-06-30 $4.55B $14.74B 0.31
2008-03-31 $4.65B $14.91B 0.31
2007-12-31 $4.59B $13.50B 0.34
2007-09-30 $4.53B $12.95B 0.35
2007-06-30 $4.57B $11.56B 0.40
2007-03-31 $4.62B $11.53B 0.40
2006-12-31 $3.49B $10.98B 0.32
2006-09-30 $4.55B $13.06B 0.35
2006-06-30 $5.58B $11.93B 0.47
2006-03-31 $5.61B $11.69B 0.48
2005-12-31 $5.76B $10.79B 0.53
2005-09-30 $5.88B $11.38B 0.52
2005-06-30 $4.45B $10.27B 0.43
2005-03-31 $4.36B $11.60B 0.38
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $116.324B $22.871B
Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $387.009B 18.15
Pfizer (PFE) United States $255.437B 14.40
Novartis AG (NVS) Switzerland $202.383B 17.29
Merck (MRK) United States $199.761B 17.31
AbbVie (ABBV) United States $132.837B 11.79
Sanofi (SNY) France $113.065B 14.00
Novo Nordisk (NVO) Denmark $108.639B 17.64
AstraZeneca (AZN) United Kingdom $104.862B 13.02
GlaxoSmithKline (GSK) United Kingdom $101.405B 13.63
Bristol-Myers Squibb (BMY) United States $85.837B 14.14